Prevalence and factors associated with potential clinically significant drug-drug interactions in patients with cardiovascular diseases at hospital admission

1World Health Organization, Cardiovascular diseases (CVDs), July 2024; https://www.who.int/europe/news-room/fact-sheets/item/cardiovascular-diseases; last access date November 4, 2024.Search in Google Scholar

2EUROSTAT, Population Structure and Ageing, February 2024; https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing; last access date July 25, 2024.Search in Google Scholar

3M. E. Tinetti, T. R. Fried and C. M. Boyd, Designing health care for the most common chronic condition–multimorbidity, JAMA 307(23) (2012) 2493–2494; https://doi.org/10.1001/jama.2012.5265Search in Google Scholar

4S. M. Dunlay and A. M. Chamberlain, Multimorbidity in older patients with cardiovascular disease, Curr. Cardiovasc. Risk Rep. 10 (2016) Article ID 3; https://doi.org/10.1007/s12170-016-0491-8Search in Google Scholar

5V. J. Wirtz, W. A. Kaplan, G. F. Kwan and R. O. Laing, Access to medications for cardiovascular diseases in low- and middle-income countries, Circulation 133(21) (2016) 2076–2085; https://doi.org/10.1161/CIRCULATIONAHA.115.008722Search in Google Scholar

6D. P. Chew, I. A. Scott, L. Cullen, J. K. French, T. G. Briffa, P. A. Tideman, S. Woodruffe, A. Kerr, M. Branagan and P. E. Aylward; NHFA/CSANZ ACS Guideline 2016 Executive Working Group: National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand, Australian clinical guidelines for the management of acute coronary syndromes, Heart Lung Circ. 25 (2016) 895–951; https://doi.org/10.1016/j.hlc.2016.06.789Search in Google Scholar

7J. Tamargo, K. P. Kjeldsen, E. Delpón, A. G. Semb, E. Cerbai, D. Dobrev, G. Savarese, P. Sulzgruber, G. Rosano, C. Borghi, S. Wassmann, C. T. Torp-Pedersen, S. Agewall, H. Drexel, I. Baumgartner, B. Lewis, C. Ceconi, J. C. Kaski and A. Niessner, Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, Eur. Heart J. Cardiovasc. Pharmacother. .(4) (2022) 406–419; https://doi.org/10.1093/ehjcvp/pvac005Search in Google Scholar

8G. Crescioli, A. Bettiol, R. Bonaiuti, M. Tuccori, M. Rossi, A. Capuano, S. Pagani, G. Spada, M. Venegoni, G. D. Vighi, G. Mannaioni, A. Vannacci and N. Lombardi, MEREAFaPS Study group, Risk of hospitalization associated with cardiovascular medications in the elderly italian population: A nationwide multicenter study in emergency departments, Front. Pharmacol. 11 (2021) Article ID 611102 (11 pages); https://doi.org/10.3389/fphar.2020.611102Search in Google Scholar

9C. Paradissis, N. Cottrell, I. Coombes, I. Scott, W. Wang and M. Barras, Patient harm from cardiovascular medications, Ther. Adv. Drug. Saf. 12 (2021) 1–22; https://doi.org/10.1177/20420986211027451Search in Google Scholar

10T. J. Oscanoa, F. Lizaraso and A. Carvajal, Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis, Eur. J. Clin. Pharmacol. 73(6) (2017) 759–770; https://doi.org/10.1007/s00228-017-2225-3Search in Google Scholar

11World Health Organization, The third WHO global patient safety challenge: Medication without harm, 2019; https://www.who.int/patientsafety/medication-safety/en/; last access date July 29, 2024.Search in Google Scholar

12National Institute for Health and Clinical Excellence (NICE), Medicines optimisation: The safe and effective use of medicines to enable the best possible outcomes, March 2015; https://www.nice.org.uk/guidance/ng5, last access date July 25, 2024.Search in Google Scholar

13Pharmaceutical Society of Australia, Medicine safety to be the 10th National Health Priority area, 2019; https://www.psa.org.au/, last access date July 25, 2024.Search in Google Scholar

14The Joint Commission, National Patient Safety Goals, https://www.jointcommission.org/standards/national-patient-safety-goals/, 2024; last access date July 20, 2024.Search in Google Scholar

15Institute for Safe Medication Practices, Highalert medications in acute care settings, 2018; https://www.ismp.org/recommendations/high-alertmedications-acute-list; last access date July 20, 2024.Search in Google Scholar

16F. Salvi, A. Marchetti, F. D’Angelo, M. Boemi, F. Lattanzio and A. Cherubini, Adverse drug events as a cause of hospitalization in older adults, Drug Saf. 35(1) (2012) 29–45; https://doi.org/10.1007/BF03319101Search in Google Scholar

17C. Cahir, Curran C. Curran, C. Walsh, A. Hickey, R. Brannigan, C. Kirke, D. J. Williams and K. Bennett, Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients, Front Pharmacol. 13 (2023) Article ID 1029067 (10 pages); https://doi.org/10.3389/fphar.2022.1029067Search in Google Scholar

18J. G. Naples, J. T. Hanlon, K. E. Schmader and T. P. Semla, Recent literature on medication errors and adverse drug events in older adults, J. Am. Geriatr. Soc. 64(2) (2016) 401–408; https://doi.org/10.1111/jgs.13922Search in Google Scholar

19M. Tissot, M. B. Valnet-Rabier, T. Stalder, S. Limat, S. Davani and V. Nerich, Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance dana, Therapie 77(3) (2022) 291–300; https://doi.org/10.1016/j.therap.2021.12.007Search in Google Scholar

20K. Dalton and S. Byrne, Role of the pharmacist in reducing healthcare costs: current insights, Integr. Pharm. Res. Pract. . (2017) 37–46; https://doi.org/10.2147/IPRP.S108047Search in Google Scholar

21M. Jermini, C. Fonzo-Christe, K. Blondon, C. Milaire, J. Stirnemann, P. Bonnabry and B. Guignard, Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis, Int. J. Clin. Pharm. 46(2) (2024) 496–505; https://doi.org/10.1007/s11096-023-01683-wSearch in Google Scholar

22L. Magro, E. Arzenton, R. Leone, M. G. Stano, M. Vezzaro, A. Rudolph, I. Castagna and U. Moretti, Identifying and characterizing serious adverse drug reactions associated with drug-drug interactions in a spontaneous reporting database, Front. Pharmacol. 11 (2021) Article ID 622862 (9 pages); https://doi.org/10.3389/fphar.2020.622862Search in Google Scholar

23C. S. Moura, F. A. Acurcio and N. O. Belo, Drug-drug interactions associated with length of stay and cost of hospitalization, J. Pharm. Pharm. Sci. 12(3) (2009) 266–272; https://doi.org/10.18433/j35c7zSearch in Google Scholar

24J. P. Schmitt, A. Kirfel, M. T. Schmitz, H. Kohlhof, T. Weisbarth and M. Wittmann, The impact of drug interactions in patients with community-acquired pneumonia on hospital length of stay, Geriatrics (Basel) .(1) (2022) Article ID 11 (9 pages); https://doi.org/10.3390/geriatrics7010011Search in Google Scholar

25L. Zerah, S. Henrard, I. Wilting, D. O’Mahony, N. Rodondi, O. Dalleur, K. Dalton, W. Knol, M. Haschke and A. Spinewine, Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial, BMC Geriatr. 21(1) (2021) Article ID 571 (11 pages); https://doi.org/10.1186/s12877-021-02532-zSearch in Google Scholar

26T. Roblek, T. Vaupotic, A. Mrhar and M. Lainscak, Drug-drug interaction software in clinical practice: a systematic review, Eur. J. Clin. Pharmacol. 71(2) (2015) 131–142; https://doi.org/10.1007/s00228-014-1786-7Search in Google Scholar

27R Core Team: A language and environment for statistical computing. R Foundation for Statistical Computing, 2018; https://www.R-project.org/; last access date 20 July 2024.Search in Google Scholar

28B. Guthrie, B. Makubate, V. Hernandez-Santiago and T. Dreischulte, The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995–2010, BMC Med. 13 (2015) Article ID 74 (10 pages); https://doi.org/10.1186/s12916-015-0322-7Search in Google Scholar

29K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke and B. Guthrie, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, Lancet 380(9836) (2012) 37–43; https://doi.org/10.1016/S0140-6736(12)60240-2Search in Google Scholar

30M. Petrovic, T. van der Cammen and G. Onder, Adverse drug reactions in older people: detection and prevention, Drugs Aging 29(6) (2012) 453–462; https://doi.org/10.2165/11631760-000000000-00000Search in Google Scholar

31J. E. Hughes, V. Russo, C. Walsh, E. Menditto, K. Bennett and C. Cahir, Prevalence and factors associated with potential drug-drug interactions in older community-dwelling adults: A prospective cohort study, Drugs Aging 38(11) (2021) 1025–1037; https://doi.org/10.1007/s40266-021-00898-8Search in Google Scholar

32L. A. Stevens, J. Coresh, T. Greene and A. S. Levey, Assessing kidney function – measured and estimated glomerular filtration rate, N. Engl. J. Med. 354(23) (2006) 2473–2483; https://doi.org/10.1056/NEJMra054415Search in Google Scholar

33N. M. P. Maideen, Adverse effects associated with long-term use of proton pump inhibitors, Chonnam Med. J. 59(2) (2023) 115–127; https://doi.org/10.4068/cmj.2023.59.2.115Search in Google Scholar

34Center for Drug Evaluation and Research, Clinical Drug Interaction Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry, January 2020; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cyto-chrome-p450-enzyme-and-transporter-mediated-drug-interactions; last access date July 10, 2024.Search in Google Scholar

35US Food & Drug Administration, Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, June 2023; https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers; last access date July 10, 2024.Search in Google Scholar

36S. F. B. van der Horst, E. S. L. Martens, P. L. den Exter, M. H. A. Bos, T. E. van Mens, M. V. Huisman and F. A. Klok, Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes, Thromb. Res. 228 (2023) 21–32; https://doi.org/10.1016/j.thromres.2023.05.020Search in Google Scholar

37S. J. Connolly, M. Sharma, A. T. Cohen, A. M. Demchuk, A. Członkowska, A. G. Lindgren, C. A. Molina, D. Bereczki, D. Toni, D. J. Seiffge, D. Tanne, E. C. Sandset, G. Tsivgoulis, H. Christensen, J. Beyer-Westendorf, J. M. Coutinho, M. Crowther, P. Verhamme, P. Amarenco, R. O. Roine, R. Mikulik, R. Lemmens, R. Veltkamp, S. Middeldorp, T. G. Robinson, T. J. Milling Jr, V. Tedim-Cruz, W. Lang, A. Himmelmann, P. Ladenvall, M. Knutsson, E. Ekholm, A. Law, A. Taylor, T. Karyakina, L. Xu, K. Tsiplova, S. Poli, B. Kallmünzer, C. Gumbinger and A. Shoamanesh; ANNEXA-I Investigators, Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage, N. Engl. J. Med. 390(19) (2024) 1745–1755; https://doi.org/10.1056/NEJMoa2313040Search in Google Scholar

38M. Kovačević, S. Vezmar Kovačević, B. Miljković, S. Radovanović and P. Stevanović, The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study, Int. J. Clin. Pract. 71(10) (2017) Article ID e13005 (9 pages); https://doi.org/10.1111/ijcp.13005Search in Google Scholar

39I. Marinović, V. Bačić Vrca, I. Samardžić, S. Marušić and I. Grgurević, Potentially inappropriate medications involved in drug-drug interactions at hospital discharge in Croatia, Int. J. Clin. Pharm. 43(3) (2021) 566–576; https://doi.org/10.1007/s11096-020-01164-4Search in Google Scholar

40I. Samardžić, I. Marinović, N. Kuča and V. Bačić Vrca, Potential clinically significant drug-drug interactions in prescribed pharmacotherapy in an outpatient setting, Pharmazie 76(8) (2021) 390–395; https://doi.org/10.1691/ph.2021.1561Search in Google Scholar

41T. Roblek, A. Deticek, B. Leskovar, S. Suskovic, M. Horvat, A. Belic, A. Mrhar and M. Lainscak, Clinical-pharmacist intervention reduces clinically relevant drug-drug interactions in patients with heart failure: A randomized, double-blind, controlled trial, Int. J. Cardiol. 203 (2016) 647–652; https://doi.org/10.1016/j.ijcard.2015.10.206Search in Google Scholar

42A. Rivkin and H. Yin, Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients, J. Crit. Care 26(1) (2011) Article ID 104.e1-104.e1046 (6 pages); https://doi.org/10.1016/j.jcrc.2010.04.014Search in Google Scholar

43S. Vik, P. Weidemann, I. E. M. Gangås, S. E. Knapstad and S. Haavik, Pharmaceutical interventions on prescriptions in Norwegian community and hospital pharmacies, Int. J. Clin. Pharm. 43(4) (2021) 872–877; https://doi.org/10.1007/s11096-020-01188-wSearch in Google Scholar

44I. A. Scott, S. N. Hilmer, E. Reeve, K. Potter, D. Le Couteur, D. Rigby, D. Gnjidic, C. B. Del Mar, E. E. Roughead, A. Page, J. Jansen and J. H. Martin, Reducing inappropriate polypharmacy: The process of deprescribing, JAMA Intern. Med. 175(5) (2015) 827–834; https://doi.org/10.1001/jamainternmed.2015.0324Search in Google Scholar

45I. A. Scott, S. N. Hilmer and D. G. Le Couteur, Going beyond the guidelines in individualising the use of antihypertensive drugs in older patients, Drugs Aging 36(8) (2019) 675–685; https://doi.org/10.1007/s40266-019-00683-8Search in Google Scholar

46E. Reeve, Deprescribing tools: A review of the types of tools available to aid deprescribing in clinical practice, J. Pharm. Pract. Res. 50 (2020) 98–107; https://doi.org/10.1002/jppr.1626Search in Google Scholar

47E. Reeve, V. Jordan, W. Thompson, M. Sawan, A. Todd, T. M. Gammie, I. Hopper, S. N. Hilmer and D. Gnjidic, Withdrawal of antihypertensive drugs in older people, Cochrane Database Syst. Rev. .(6) (2020) Article ID CD012572 (61 pages); https://doi.org/10.1002/14651858.CD012572.pub2Search in Google Scholar

48J. P. Sheppard, A. Benetos and R. J. McManus, Antihypertensive deprescribing in older adults: A practical guide, Curr. Hypertens. Rep. 24(11) (2022) 571–580; https://doi.org/10.1007/s11906-022-01215-3Search in Google Scholar